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ABSTRACT
Human papilloma virus (HPV)-induced cervical cancer constitutively expresses viral E6/E7 oncoproteins
and is an excellent target for T cell-based immunotherapy. However, not all tumor-inﬁltrating T cells
confer equal beneﬁt to patients, with epithelial T cells being superior to stromal T cells.
To assess whether the epithelial T cell biomarker CD103 could speciﬁcally discriminate the beneﬁcial
antitumor T cells, association of CD103 with clinicopathological variables and outcome was analyzed in
the TCGA cervical cancer data set (n D 304) and by immunohistochemistry (IHC) in an independent cohort
(n D 460). Localization of CD103C cells in the tumor was assessed by immunoﬂuorescence. Furthermore,
use of CD103 as a response biomarker was assessed in an in vivo E6/E7C tumor model.
Our results show that CD103 gene expression was strongly correlated with cytotoxic T cell markers (e.g.
CD8/GZMB/PD1) in the TCGA series. In line with this, CD103C cells in the IHC series co-expressed CD8 and
were preferentially located in cervical tumor epithelium. High CD103C cell inﬁltration was strongly
associated with an improved prognosis in both series, and appeared to be a better predictor of outcome
than CD8. Interestingly, the prognostic beneﬁt of CD103 in both series seemed limited to patients
receiving radiotherapy. In a preclinical mouse model, HPV E6/E7-targeted therapeutic vaccination in
combination with radiotherapy increased the intratumoral number of CD103C CD8C T cells, providing a
potential mechanistic basis for our results.
In conclusion, CD103 is a promising marker for rapid assessment of tumor-reactive T cell inﬁltration of








Cervical cancer is the most common gynecologic malignancy
and the second most common malignancy afﬂicting women
worldwide (globcan). The development of cervical cancer is
largely dependent on persistent human papilloma virus (HPV)
infections, with HPV16 and 18 being the dominant subtypes.1,2
As a virally-induced cancer, control of cervical cancer
development appears at least partly mediated by the immune
system,3-5 and multiple studies have demonstrated a clear bene-
ﬁt of T cell inﬁltration on survival in cervical cancer patients.6-9
The malignant transformation of cervical epithelial cells by
HPVs involves integration of viral oncogenes, such as HPV E6
and E7, into the cellular DNA. Subsequent expression of these
HPV E6 and E7 proteins inhibits the tumor suppressors p53
and pRb, respectively, resulting in a loss of cell cycle control,
proliferation and malignant transformation. Importantly,
sustained expression of E6 and/or E7 is required for maintaining
a malignant cellular phenotype in this setting.10 E6/E7 therefore
represent bona ﬁde cancer-speciﬁc antigens that can be targeted
for cancer immunotherapy. Indeed, T cell-based therapies target-
ing E6/E7 have met with clinical success in early trials.11-21 As
readout for therapeutic efﬁcacy of these approaches, systemic
immune monitoring in the blood is usually used alone, or in
combination with monitoring of CD8C T cell tumor inﬁltration.
Herein, a distinction is frequently made between CD8C TIL that
inﬁltrate the epithelial cancer nests or TIL that inﬁltrate the sur-
rounding stroma. This distinction is based on the known need
for contact between TIL and cancer cells for efﬁcient induction
of cell death, and the observed stronger association of epithelial
TIL compared with stromal TIL with regards to patient progno-
sis.22 However, this approach relies on distinguishing epithelial
from stromal regions, a non-trivial feat in many tumors. The
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identiﬁcation of a biomarker for identifying tumor-reactive cells
would therefore be of substantial beneﬁt.
Recently, we and others have demonstrated that CD103, also
known as the aE integrin subunit, delineates prognostically
favorable intraepithelial CD8C tumor-inﬁltrating lymphocytes
(TIL) in endometrial, ovarian, lung and bladder cancer.23-27 In
contrast to the prognostic beneﬁt observed for CD8C TIL,28,29
this survival beneﬁt was also evident when quantifying the total
number of CD103C TIL present within the tumor.23-27 This
ﬁnding is in line with the proposed restricted expression of
CD103 on CD8C TIL that have inﬁltrated the tumor epithelium.
The aim of this study was therefore to determine whether
expression of CD103 deﬁnes the intraepithelial CD8C TIL in
cervical cancer and whether CD103C TIL are associated with
improved prognosis. Further, we explored the mechanistic basis
of our ﬁndings in a preclinical mouse model and determined
whether CD103 inﬁltration could be used as a response bio-
marker for therapeutic HPV16 E6/E7-targeted immunotherapy.
Results
Expression of CD103 is an independent prognostic factor
in cervical cancer and strongly associated with an immune
signature
To investigate the utility of CD103 as a biomarker of an anti-tumor
T cell response in cervical cancer, we ﬁrst analyzed expression of
CD103 (ITGAE) mRNA in The Cancer Genome Atlas (TCGA)
cervical cancer data set. CD103 gene expression was strongly corre-
lated with the expression of T cell markers (CD3, CD2), exhaustion
molecules (PD1, TIGIT), antigen-presenting molecules (HLA-DR,
-DQ) and B cell markers (CD19) suggesting that increased CD103
expression deﬁnes a group of immunologically “hot” tumors in
this cervical cancer cohort (Fig. 1A). High CD103 expression
(>median) was associated with younger patient age (49.9 vs.
46.5 years, P D 0.03, t-test) and squamous histology (P D 0.026,
Fisher exact test), though no association with disease stage, tumor
differentiation or treatment use was observed (Supplementary
Table 1). Notably, CD103 expression greater than the median was
associated with signiﬁcantly improved cancer-speciﬁc survival
both in univariable analysis (Fig. 1B; HR D 0.56, 95%CI D 0.34–
0.92, PD 0.02) and after adjusting for disease stage inmultivariable
analysis (HR D 0.55, 95%CI D 0.32–0.94, P D 0.03) (Supplemen-
tary Table 2). By contrast, increased expression of CD8A was not
signiﬁcantly associated with cancer-speciﬁc survival in this popula-
tion (Supplementary Table 2). Exploratory analysis according to
treatment modality (surgery vs. radio(chemo)therapy) suggested
that the prognostic beneﬁt of increased CD103 expression was
observed in patients treated with radiotherapy, but not in patients
treated with surgery alone (Fig. 1C (pD 0.015) and 1D (pD 0.47),
respectively).
CD103C TIL are associated with prolonged disease-speciﬁc
and disease-free survival in cervical cancer patients
To validate our ﬁndings from the TCGA data set, we analyzed
inﬁltration of CD103C cells by immunohistochemistry (IHC)
in an independent cohort of 630 cervical cancer patients.
Patients were included for quantiﬁcation of CD103C TIL if the
tissue microarray (TMA) used contained at least 2 cores with a
minimum of 20% tumor. Representative tumor cores were
available from 460 patients. Patient and tumor characteristics
did not differ between analyzed and excluded patients (data not
shown). Table 1 shows the patient and tumor characteristics of
the patients eligible for CD103 quantiﬁcation. Of the 460
included patients, 123 were treated with surgery alone and 337
were treated with radio(chemo)therapy (R(C)T) (alone or in
combination with surgery). The surgery cohort consisted of
patients diagnosed with Federation Internationale de
Gynecologie Obstetrique (FIGO) stages IB1-IIA. The R(C)T
cohort consisted of patients diagnosed with FIGO stages IB1-
IVA. The majority of patients in the surgery cohort were diag-
nosed with FIGO IB1 (n D 86; 69.9%) and the majority of
patients in the R(C)T cohort were diagnosed with FIGO stage
IIB (n D 112; 33.2%). Of the surgery and R(C)T cohort, 64.2%
(n D 79) and 78.9% (n D 266) of tumors were squamous cell
carcinomas (SCC) and 17.9% (n D 22) and 13.1% (n D 44)
were adenocarcinomas (AC), respectively. The median follow-
up time was 5.12 y with a maximum of 21.31 years. Positive
staining for CD103C TIL was equally present in SCC, AC and
other subtypes (Supplementary Figure S1A). Interestingly, the
median inﬁltration of CD103C cells in patients that received
radio(chemo)therapy was signiﬁcantly lower than for patients
that received surgery alone (Table 1; median surgery 55 vs. 24
R(C)T; p < 0.0001). Further, within the R(C)T cohort, patients
with a higher FIGO stage were characterized by a lower number
of CD103C cells (Table 1; median 38 in IB1 vs. 20 in IIB and 11
in IIIB; p < 0.05 and p < 0.01, respectively). Likewise, adeno-
carcinomas in the R(C)T cohort were inﬁltrated less than squa-
mous cell carcinomas (Table 1; median 25 vs. 13; p < 0.05). To
analyze survival, patients were dichotomized based on high or
low/no inﬁltration and the cohorts treated with either surgery
or radio(chemo)therapy were analyzed together or separately.
The cut-off was determined based on median CD103CTIL
inﬁltration of the total cohort and was 29 cells/mm2. Disease-
speciﬁc survival (DSS) analysis based on inﬁltration of
CD103C cells revealed a signiﬁcant improved survival in the
total cohort (Fig. 2A; p < 0.0001), a nonsigniﬁcant improve-
ment of survival in the cohort treated with surgery only
(Fig. 2B; p D 0.9947) and a signiﬁcant improvement of survival
in the radio(chemo)therapy cohort (Fig. 2C; p D 0.0032). Simi-
lar results were obtained when determining disease-free sur-
vival (Fig. 2D–E; p D 0.0004 for the total cohort, p D 0.7350
for surgery alone, and p D 0.0072 for R(C)T). In analysis of the
total cohort, additional prognostic factors were stage (HR D
4.19, p < 0.001), use of radio(chemo)therapy (HR D 1.49,
p < 0.001) and tumor diameter (HR D 2.9; p < 0.001) (Supple-
mentary Table 3). In multivariate analysis, stage (HR D 2.43,
p < 0.006), use of radio(chemo)therapy (HR D 1.30,
p < 0.001) and CD103C cells (HR D 0.67, p < 0.027) were
independent prognostic factors (Supplementary Table 3).
CD103 demarcates intraepithelial CD8C TIL in cervical
cancer
To investigate the localization and the phenotype of CD103C
TIL in cervical cancer, 18 tumors containing high levels of
CD103C TIL were selected, and tumor sections were stained for





























CD3, CD8, FoxP3, NKp46, ﬁbronectin, DAPI, and CD103. For
each section, cell inﬁltration was quantiﬁed for at least three
independent regions. When examining the localization of the
TIL we noticed different patterns of stromal inﬁltration into the
epithelial areas previously classiﬁed as ‘pushing’ tumors and ‘des-
moplastic’ tumors.30 Due to their distinctive nature, both types
of tumors were subsequently analyzed separately (Fig. 3A).
Fluorescent staining of the pushing tumor type (n D 12)
showed that CD103C TIL were preferentially localized
within the tumor epithelium and not within the tumor
stroma (Fig. 3A). Furthermore, these intraepithelial
CD103C TIL largely co-expressed CD8 (Fig. 3B). A subset
of CD103C TIL in the pushing tumor type did not express
CD8 (Fig. 3C–D). Further analysis of these CD8- CD103C
TIL showed that these cells did express CD3 and could
therefore represent CD4C regulatory T cells (Treg) or natu-
ral Killer T cells (NKT) (Supplementary Fig. 2).
Interestingly, the CD3C CD8- CD103C TIL did not express
NKP46 or FoxP3 (Supplementary Figs. 3 and 4, respec-
tively) suggesting a CD3C CD4C non-Treg phenotype.
Within the desmoplastic tumor type (n D 6), a distinct selec-
tion of stromal versus epithelial areas could not be made
(Fig. 3A–B). Nevertheless, the desmoplastic tumors contained
an even higher percentage of CD8C CD103CTIL (Fig. 3D). By
contrast, single CD8C or CD103C cells could barely be detected
in these tumors. In healthy cervical tissue, no CD8C CD103C
cells were detected (Fig. 3A), but epithelial CD8C CD103- cells
and a small number of stromal CD8- CD103C cells were found.
Untransformed stromal cervical tissue surrounding the pushing
tumor types was frequently rich in CD8- CD103- cells that
expressed NKp46 (data not shown). Taken together, these data
demonstrate that CD103C cells in cervical cancer tissue are pre-
dominantly CD8C T cells, with a minor fraction of CD4C non-
Treg cells. By contrast, CD103C T cells are largely absent from
Figure 1. CD103-associated immune responses and clinical outcome in TCGA cervical cancers. A) Heatmap showing expression of immunologic genes according to tumor
histology and ordered by CD103 (ITGAE) expression. RSEM-normalized RNAseq expression data were log2 transformed, mean centered and assigned unit variance. For
each gene, the correlation with CD103 expression was calculated by spearman rho. B-D) Kaplan–Meier curves demonstrating cancer survival of patients in the TCGA series
dichotomized by median CD103 (ITGAE) expression for the total cohort (B) and according to radiotherapy treatment (C, D) (note that survival data were not available for






























untransformed epithelium and stroma. In tumor-adjacent
stroma, mainly CD103- NK cells are present.
CD103C TIL in situ are characterized by ongoing
TGFbR1-signaling
We and others have demonstrated that CD103 is upregulated
on T cells following concomitant T cell and transforming
growth factor (TGF)-b receptor (TGFbR) signaling.31-35
Indeed, CD103C, but not CD103-, TIL in high-grade serous
ovarian cancer are characterized by nuclear phosphorylated
mothers against decapentaplegic homolog 2 and 3 (pSMAD2/
3) expression, a hallmark of TGF-b signaling. To conﬁrm signs
of active TGF-b signaling in CD103C TIL from SCC, parafﬁn-
embedded tissue was probed by ﬂuorescent microscopy for
simultaneous expression of CD8, CD103 and nuclear
pSMAD2/3. SCC tumor islets, the surrounding stroma cells,
and CD103- and CD103C TIL were all characterized by a pro-
nounced nuclear expression of pSMAD2/3 (Fig. 4) suggesting
TGFbR1-signaling is highly active in the cervical cancer
microenvironment, but not restricted to CD103C TIL. In
healthy cervical tissue, pSMAD2/3 signaling was also abundant
in epithelial, stromal, CD8C and CD103C cells (Supplemen-
tary Fig. 5).
Anti-tumor therapeutic efﬁcacy is mediated by recruitment
of CD103C TIL in vivo
Finally, to determine whether CD103 could also be used as a
response biomarker for immunotherapy targeting E6 and E7,
we used the E6/E7-transformed TC1 mouse model.36 TC-1 cells
are derived from primary epithelial cells of C57BL/6 mice co-
transformed with HPV-16 E6 and E7 and c-Ha-ras oncogenes.
These cells form tumors composed largely of epithelial cells
after subcutaneous injection and should therefore induce
CD103 on inﬁltrating CD8C T cells. Based on the differential
prognostic effects of radiotherapy observed in both the TCGA
and IHC series, we also assessed whether radiotherapy syner-
gized with E6/E7-speciﬁc antitumor immune responses in vivo
using our previously published experimental setup36 (Fig. 5A).
Table 1. Patient characteristics of the IHC cohort.
Variables N D 460 Surgery n (%) CD103 median (range) (chemo-) RT n (%) CD103 median (range) Total n (%) CD103 median (range)
Patients 123 (26.7) 55 (1–367) 337 (73.3) 24 (0–256) 460 (100) 29 (0–367)
Age at diagnosis (in years)
Median 41.2 50.7 47.7
Range (24.4–84.7) (20.6–92.0) (20.6–92.0)
FIGO stage
IA2 0 (0) 0 (0) 0 (0)
IB1 86 (69.9) 52 (1–367) 77 (22.8) 38 (0–256) 163 (35.4) 50 (0–367)
IB2 20 (16.3) 83 (7–286) 50 (14.8) 23 (2–204) 70 (15.2) 31 (2–286)
IIA 17 (13.8) 80 (10–203) 60 (17.8) 23 (0–215) 77 (16.7) 29 (0–215)
IIB 0 (0) 112 (33.2) 20 (1–150) 121 (24.3) 20 (1–150)
IIIA 0 (0) 4 (1.2) 16 (5–34) 4 (0.9) 16 (5–34)
IIIB 0 (0) 28 (8.3) 11 (0–115) 28 (6.1) 11 (0–115)
IVA 0 (0) 6 (21.8) 16 (5–43) 6 (1.3) 16 (5–43)
Histology
Squamous cell carcinoma 79 (64.2) 82 (7–367) 266 (78.9) 25 (1–215) 345 (75.0) 30 (1–367)
Adenocarcinoma 22 (17.9) 53 (6–246) 44 (13.1) 13 (0–256) 66 (14.3) 16 (0–256)
Other 22 (17.9) 33 (1–186) 27 (8.0) 36 (4–199) 49 (10.7) 36 (1–286)
Grade of differentiation
Good/moderate 69 (56.1) 55 (1–367) 190 (56.4) 24 (0–215) 259 (56.3) 29 ( 0–367)
Poor/undifferentiated 51 (41.5) 83 (3–303) 129 (38.3) 26 (0–256) 180 (39.1) 33 (0–304)
Unknown 3 (2.4) 52 (6–53) 18 (5.3) 14 (3–120) 21 (4.6) 16 (3–120)
Lymphangioinvasion
No 74 (60.2) 56 (5–367) 173 (51.3) 22 (0–216) 247 (53.7) 28 (3–367)
Yes 49 (39.8) 55 (1–304) 105 (31.2) 35 (2–256) 154 (33.5) 38 (1–304)
Unknown 0 (0) 59 (17.5) 16 (0–128) 59 (12.8) 16 (0–128)
Tumor diameter
0–4 cm 97 (78.9) 52 (1–367) 118 (35.0) 36 (0–256) 215 (46.7) 40 (0–367)
 4 cm 26 (21.1) 86 (6–286) 203 (60.2) 18 (0–204) 229 (49.9) 22 (0–286)
Unknown 0 (0) 16 (4.7) 33 (3–128) 16 (3.5) 33 (3–128)
Treatment
WM 123 (100) 55 (1–367)
WMC post operative RT 83 (24.6) 42 (2–256)
WMC Post operative RCT 14 (4.2)) 33 (2–84)
Primary RT 115 (34.1) 22 (0–198)
Primary RCT 125 (37.1) 16 (0–133)
Follow-up (in years)
Median 5.62 4.81 5.12
Range (0.53–16.93) (0.14–21.31) (0.14–21.31)
Result last follow-up
No evidence of disease 109 (88.6) 77 (3–367) 168 (49.9) 29 (0–216) 227 (60.2) 38 (0–367)
Evidence of disease 2 (1.6) 92 (1–184) 2 (0.6) 52 (3–102) 4 (0.9) 52 (1–184)
Death of other disease 0 (0) 33 (9.8) 24 (0–215) 33 (7.2) 24 (0–215)
Death of disease 12 (9.8) 42 (7–170) 134 (39.8) 15 (0–256) 146 (31.7) 17 (0–256)
Abbreviations: FIGO: International Federation of Gynecologists and Obstetricians
WM: Wertheim Meigs RT: Radiotherapy RCT: Radio-chemotherapy





























In brief, female C57BL/6 mice were challenged with TC1
tumors and treated with a suboptimal immunization regimen
of 5 £ 106 i.u. semliki forest virus (SFV)eE6,7 immunization 14
days after tumor inoculation with or without radiation. At this
dose, immunization alone is insufﬁcient at inducing tumor
eradication and synergizes with ionizing radiation. After 22
days mice were killed, tumors were measured and digested.
For ﬂow cytometric analysis, TC1 tumor digests were gated
on lymphocyte singlets and subsequently on DAPI- live cells
(Fig. 5B). Within the TC1 tumor digests, untreated mice
showed »10% CD8C CD103C cells (Fig. 5C–D). Therapeutic
SFVeE6/E7 vaccination increased the intratumoral number of
CD8C CD103C T cells to »25%, an effect that further syner-
gized with concomitant irradiation to »60% (representative
plots in Fig. 5C). Irradiation alone resulted in a »10% CD8C
CD103C T cell inﬁltration (Fig 5C–D). Within all treatment
groups, and independent of the number of inﬁltrating cells,
CD103C cells were almost exclusively CD8C T cells (Fig. 5C).
As expected, the percentage of inﬁltrating CD8C CD103C T
cells across all treatment groups was negatively correlated with
tumor weight (Fig. 5E; R2 D 0.53 p D 0.008). Finally, analysis
of E7-reactive T cells using E7 H-2Kb dextramer staining
revealed E7-speciﬁcity to be largely restricted to the CD103C T
cell population (Fig. 5F).
Discussion
In the present study we demonstrate that inﬁltrating CD103C
T cells are a prognostic factor for survival in cervical cancer
patients. By gene expression analysis on tumor samples from
cervical cancer patients available within the TCGA data set, we
showed that expression of ITGAE, the gene encoding for
CD103, correlates with signiﬁcantly improved survival. This
prognostic beneﬁt of CD103-expressing T cells was conﬁrmed
in an independent cohort of 460 cervical cancer patients by
immunohistochemical analysis of CD103C TIL in FFPE-tumor
cores. Furthermore, we show that CD103 is a marker for intrae-
pithelial CD8C T cells in cervical cancer. Finally, we demon-
strate that CD103 holds considerable promise as both a
predictive and response biomarker for radiotherapy and/or E6/
E7-targeted immunotherapy.
Our results in the cervical cancer cohorts are in line with ear-
lier ﬁndings on the localization and prognostic inﬂuence of
CD103C TIL in endometrial, ovarian, bladder and lung cancer.
Figure 2. CD103C TIL are strongly associated with survival in patients with cervical cancer. A) Disease-speciﬁc survival (DSS) of patients within the total cohort according
to high or low inﬁltration of CD103C cells (p < 0.0001). B) DSS of patients treated with surgery alone with a high or low inﬁltration of CD103C cells. C) DSS of patients
treated with radio(chemo)therapy and either a high or low inﬁltration of CD103C cells. D) Disease-free survival (DFS) of patients within the total cohort according to high
or low inﬁltration of CD103C cells (p D 0.0004). E) DFS of patients treated with surgery alone with a high or low inﬁltration of CD103C cells. F) DFS of patients treated






























Figure 3. CD103 demarcates intraepithelial CD8C TIL in cervical cancer tissue. A) Representative image of tissue from a normal cervix, from a patient with cervical cancer
of the “pushing” type and of a patient with cervical cancer of the “desmoplastic” type stained with DAPI (DNA, orange), anti-CD8 (yellow), anti-CD103 (blue) and anti-
ﬁbronectin (green) antibodies. B) Representative images of CD8C and CD103C cells in the epithelial or stromal areas of 40 mm2 of tumor tissue. C) Representative single
and multichannel images of tumor areas showing co-expression of CD8 and CD103. D) Quantiﬁcation of single CD8C, single CD103C or CD8C CD103C double-positive
cells in the stroma and epithelial areas of the “pushing” tumors or total of the “desmoplastic” tumors. Each data point represents a cell count from a 40mm2 independent
region of 18 independent tumors (3–6 in total per tumor section). Groups were compared by ANOVA using a Dunns post-test. p < 0.05, p < 0.01, p < 0.001.





























Figure 4. TGF-b signaling is abundant in cervical cancer tissue. A) Representative image of tissue from a patient with cervical cancer of the “pushing” type stained with
DAPI (DNA, orange), anti-CD8 (yellow), anti-CD103 (blue) and anti-pSMAD2/3 (green) antibodies. B) Representative single and multichannel images of the tumor area
from A showing predominant localization of CD8C cells in the pSMAD2/3C stromal region and CD8C CD103C cells in the pSMAD2/3C epithelial region. Insets represent
areas magniﬁed in panels C and D. C-D) Representative images of CD8C and CD103C cells in magniﬁed epithelial (C) or stromal areas (D) of tumor tissue as indicated by
insets in B. E) Quantiﬁcation of CD8C, CD103C and/or pSMAD2/3C cells in the stroma and epithelial areas of the “pushing” tumors or total of the “desmoplastic” tumors.
Each data point represents a cell count from a 40mm2 independent region of 18 independent tumors (3–6 in total per tumor section). Groups were compared by ANOVA






























Figure 5. Combination immunotherapy targeting HPV E6 and E7 induces accumulation of CD103C cells in vivo. A) Schematic depiction of the TC1 mouse model. B) Rep-
resentative ﬂow cytometric plot of a TC1 tumor digest analyzed for expression of CD103 and CD8 within the DAPI-negative live cell population. C) Representative ﬂow
cytometric plots of TC1 tumor digests from untreated mice or mice treated with irradiation, a low dose of SFV E6/E7 vaccine, or both analyzed for expression of CD8 and
CD103 within the DAPI-negative live cell population. D) Bar graphs representing the absolute number of CD103C cells per gram of tumor of the experimental groups
(n D 3–6). E) Scatter plots representing the number of CD103C cells per gram of tumor across all groups (n D 3–6). F) Percentage of E7-speciﬁc CD8C T cells across all
treatment groups. p < 0.05.





























However, in contrast to other malignancies, inﬁltration of cervi-
cal cancers was related to the type of treatment patients received
and the stage of disease. Patients that were treated with radio
(chemo)therapy alone or in combination with surgery had
fewer inﬁltrating CD103C TIL compared with patients that
qualiﬁed for surgical treatment alone. Moreover, within the
radio(chemo)therapy group, patients that presented with a
higher stage of disease were characterized by even lower num-
bers of CD103C TIL when compared with patients with lower
FIGO stages. This strongly suggests an interference of T cells
and tumor cells where an equilibrium is reached in the early
stages of disease, whereas larger tumors have escaped immune
control by T cells and advanced stages of the disease are able to
develop.37 As a result, patients with immunological ‘hot’ tumors
generally present with an early stage of disease, whereas patients
with immunological ‘cold’ tumors show a more aggressive dis-
ease with indications for primary (locally advanced disease) or
adjuvant radio(chemo)therapy treatment (e.g., positive resec-
tion margins after surgery or positive lymph nodes).
In addition to the reduced number of inﬁltrating cells in
clinically more aggressive cancers, analysis of the TCGA cervi-
cal cancer data set shows that ITGAE expression is not only
strongly associated with the common T cell genes such as
CD8A, but more importantly also with T cell activation and
exhaustion markers such as CD137, CTLA4, PD1, and PDL1.
This suggests that these patients may be candidates for addi-
tional adjuvant therapy with immune checkpoint inhibitors
such as antibodies targeting CTLA-4 (ipilimumab) or PD-1
(nivolumab/pembroluzimab). In patients with melanoma and
non-small cell lung cancer in particular, immune checkpoint
inhibitors have met with considerable clinical success. In these
malignancies, responses to immune checkpoint inhibitors have
been strongly linked to the presence of neo-antigens in cancer
cells (particularly those expressed across lesions) that provide a
true tumor-speciﬁc target for T cells for which tolerance has
likely not been established.38,39 In cervical cancer, the constitu-
tive expression and the viral nature of E6/E7 oncoproteins in
malignant cells is likely to provide a similar strong and non-tol-
erant target for T cell recognition that may be exploited with
immune checkpoint inhibitors.
One caveat herein may be the poor inﬁltration of these
tumors by immune cells. Indeed, as discussed above, aggressive
tumors at higher stages of the disease show relatively poor inﬁl-
tration by CD103C TIL that may preclude effective responses
to checkpoint inhibition. In one melanoma trial, a high number
of preexisting T cells was a determinant for subsequent
responses to therapy with anti-PD1 antibody pembroluzimab.
In the absence of a strong T cell response, additional therapeu-
tic strategies may therefore be required to pre-condition these
patients for therapy with checkpoint inhibitors.40 One promis-
ing approach is the use of therapeutic vaccins targeting the E6/
E7 oncoproteins. Indeed, several clinical trials have demon-
strated promising results in cervical intraepithelial neoplasia
(CIN) and cervical cancer patients treated with therapeutic E6/
E7 targeted vaccines.11,16,18,19,41 In one study using a therapeu-
tic DNA vaccine, 7 out of 9 CIN 3 patients showed complete
regression and viral clearance within 36 weeks of follow up.16
In a randomized, double-blind, placebo-controlled trial in
CIN2/3 patients, 49.5% of the DNA vaccine recipients showed
regression of the disease vs. 30.6% in the control group.11 These
promising results may eventually lead to a change in treatment
strategy for CIN 2/3, in which therapeutic vaccination could
represents a non-surgical option.
In this work, we similarly demonstrate that an E6/E7-
targeted SFV vaccine can induce accumulation of CD103C T
cells in tumors in vivo, an effect that synergized with radiother-
apy. SFV E6/E7 vaccination therefore not only promotes sys-
temic immune responses, but T cells induced by this
vaccination effectively penetrate the tumor lesion and engage
the epithelial cells present, resulting in CD103 upregulation.
Importantly, all inﬁltrating cells in this model were CD8C, in
line with the phenotype observed in the human setting.
With regards to this phenotype and ontogeny of CD103C TIL
in human tumors the literature remains diverse. In the gut,
CD103 has been described to be expressed on Intra-epithelial
Lymphocytes (IEL), characterized by a CD8aaC phenotype.42,43
In NSCLC the phenotype of CD103C TIL has been described as
tissue-resident memory T cells (characterized by a CD69C
CD62L¡ CD28¡ CD27C CD45RAC CD45ROC CCR7- phe-
notype).24 In endometrial cancer CD103C TIL were of heteroge-
nous memory phenotypes,34 and in HGSC, CD103CTIL were
classical CD3C CD56- TCRabC CD8abC CD4- T cells, also
with heterogeneous differentiation status.35 While we demon-
strate dominant CD8 co-expression in cervical cancer, the precise
differentiation status has not been investigated. We hypothesize
that, as the cervix functions as a barrier against pathogens,
CD103 tissue-resident memory T cells may also be present.
However, in the context of tumor-speciﬁc (E6/E7-directed)
immune responses, the majority of CD103C TIL are likely
recruited as a result of an adaptive immune response. Within cer-
vical cancer tumor slides, we also show that CD103C CD8- TIL
expressed CD3 but were negative for NkP46 and FoxP3, suggest-
ing a CD4 but not a NKT cell nor a Treg origin.
Interestingly, when analyzing the ﬂuorescent images of the
tumor tissue we noticed different patterns of stromal inﬁltra-
tion into the epithelial areas, namely a pushing and desmoplas-
tic type.30 The pushing tumor type was characterized by a
distinct separation of epithelial and stromal areas. Whereas in
the desmoplastic tumor type, a separation between stromal vs.
epithelial areas could not be made. The desmoplastic tumor
type has been described in literature as a more invasive tumor,
but the exact consequences of this remains unclear. Interest-
ingly, we observed that the desmoplastic tumors contained an
even higher percentage of CD8C CD103CTIL when compared
with the pushing type. This might suggest that the desmoplastic
tumors are more accessible to inﬁltration of CD8C T cells
which then engage the epithelial tumor cells and upregulate
CD103 after T cell receptor (TCR) activation.
In line with this hypothesis, our data strongly suggests that
upregulation of CD103 in cervical cancer is mainly the result of
TCR signaling upon cancer cell contact. It has been well estab-
lished that ITGAE (CD103) expression is induced by dual TCR
and TGFbR1 activation.32,33,44 In HGSC, we have further shown
that CD103C, but not CD103-, TIL are characterized by nuclear
pSMAD2/3 expression, a hallmark of TGF-b signaling.35 In con-
trast to HGSC tissue, the total tumor microenvironment in cervi-
cal cancer tissue was rich in pSMAD2/3 expression and no






























were observed. This TGF-b rich microenvironment might be
explained by the E6/E7-dependent ontogeny of cervical cancer.
HPV-16 E6 and E7 oncoproteins have been shown to directly
regulate the TGF-b1 promoter in cervical tumor cells through a
speciﬁc DNA sequence motif in the TGF-b1 core promoter.45 It
is thought the upregulation of TGF-b facilitates the development
of cervical neoplasia after E6/E7 integration by promoting geno-
mic instability in the infected epithelial cells.46 As a consequence,
the immune environment is rich in TGF-b expression likely ren-
dering T cell contact with the cancer cell as the key determinant
of CD103 induction. CD103 may therefore represent an excellent
biomarker for tumor-reactive T cells in cervical cancers that
could be quantiﬁed in a rapid manner without having to account
for epithelial vs. stromal compartments. It is tempting to specu-
late that the same may therefore hold true for other types of
HPV-mediated cancers, such as head and neck squamous cell
carcinoma (HNSCC). Indeed, TGF-b is overexpressed in »80%
of HNSCC cases47 and likely produced by both cancer cells,
stroma, and/or inﬁltration immune cells (reviewed in Yang
et al.48) It will be interesting to assess whether differences exist
between CD103C cells inﬁltration in HPV-positive vs. HPV-neg-
ative HNSCC tumors, as has been reported for CD8C cells.49
This use of CD103 as an easy-to-use biomarker for assessing
immune responses against cervical cancer is supported by our in
vivo data that demonstrate increased inﬁltration of TC1 tumors
by CD103C CD8C cells upon treatment with a synergizing
combination of HPV E6/E7 vaccination and radiotherapy.
Indeed, an inverse correlation exists between the number of
CD103C cells in the tumor digest and the size of the tumor.
With the clinical advent of therapeutic E6/E7-based vaccination
strategies, CD103 may be incorporated both for patient selection
and for monitoring early therapy responses in the tumor by
biopsy. Of note, clues for synergistic effects on tumor control for
radiation and E6/E7-targeted therapy in the human setting were
also found in this study. In particular, the prognostic beneﬁt of
CD103C cell inﬁltration in both the TCGA and IHC data sets
were found within the group of patients that received adjuvant
radio(chemo)therapy within 6 months of surgical intervention,
but not in patients that received surgery alone. Assuming inﬁl-
trating T cells in most patients react against E6/E7 proteins to a
certain extent, it is tempting to speculate that the pre-existing
immune responses are augmented by the radiotherapy, similar
to what was observed in the animal model. Future studies on
clinical vaccination in combination with radiotherapy therefore
appear warranted in this patient population.
Taken together, we demonstrate here for the ﬁrst time that
CD103 is a suitable marker for rapid unbiased assessment of prog-
nostically beneﬁcial CD8C T cell inﬁltration of cervical cancers
and might be used as a response biomarker for E6/E7-targeted
immunotherapy alone or in combination with radiotherapy.
Methods
TCGA data and analysis
TCGA RSEM normalized50 RNAseq and clinical data were down-
loaded from FireBrowse (http://ﬁrebrowse.org) on August 22nd,
2016. After removal of normal tissue controls and technical dupli-
cates, 304 cervical cancer cases were informative for this study.
RNAseq data were log2 transformed before further analysis. The
expression of CD103 (ITGAE) relative to that of other immune
markers51 was visualized by means of a heatmap using GENE-E
(Broad Institute). For analysis of CD103 expression with clinico-
pathological variables and patient survival, cases were dichoto-
mized according to median CD103 expression. Analyses of clinical
outcome excluded 13 patients for whom survival data were not
available. For the exploratory analyses of the relationship between
CD103 expression, radiotherapy treatment and clinical outcome,
we excluded cases in which radiotherapy was given  6 months
after diagnosis, to avoidmisclassiﬁcation of patients irradiated after
disease recurrence.
Patient selection for the immunohistochemical series
Clinicopathological characteristics of cervical cancer patients
treated within the University Medical Center Groningen were
prospectively stored in a database since January 1980. As
described by Maduro et al,52 a separate anonymized database
was retrieved containing all patients with stage IA2-IVA cervical
cancer. Patients were treated between January 1980 and Decem-
ber 2004 with either surgery or radiotherapy depending on stage
of disease and/or results of surgical outcome. We categorized
patients into two groups based on their treatment modality,
namely surgery or radio(chemo)therapy. The treatment modality
was considered surgery in those patients in whom a radical hys-
terectomy combined with pelvic lymph node dissection was per-
formed (ﬁrst choice of treatment in early stage disease). The
treatment modality was considered radio(chemo)therapy (ﬁrst
choice of treatment in locally advanced disease) if patients
received radiotherapy or radio-chemotherapy, even if a surgical
procedure was performed, as is the case in e.g., patients where
positive nodes are detected after primary hysterectomy/lymph
node dissection. Patients were selected if sufﬁcient formalin-
ﬁxed, parafﬁn-embedded (FFPE) tissue was available for tissue
microarray (TMA) construction. For the construction of the
TMA, only pretreatment biopsies were used. Follow up data was
collected up to April 2012. According to Dutch law, no approval
from our institutional review board was needed.
Tissue microarray (TMA) construction
From the patients meeting the inclusion criteria, a TMA was
constructed as described previously.53 In brief, cancer nests were
determined by a gynecologic pathologist based on H&E staining.
Triplicate 1mm2 cores were randomly selected from cancer nests
and placed in a recipient parafﬁn block by a tissue microarrayer
(Beecher instruments). After insertion of cores, recipient blocks
were placed at 37C for 15 minutes to maximize tissue adhesion
to the wax. The parafﬁn block was sliced into 4mm sections and
placed on APES-coated slides (Starfrost).
Immunohistochemical analysis of CD103§ TIL inﬁltration
TMA sections were dewaxed in xylene and rehydrated using
degraded concentrations of ethanol to distilled water. Antigen
retrieval was initiated using a preheated 10 mM citrate buffer
(pH6), endogenous peroxidase activity was blocked by sub-
merging of sections in a 0.45% H2O2 solution. Sections were





























incubated in a blocking buffer (1% human AB serum in 1%
BSA/PBS solution), followed by an avidin/biotin block. After-
wards, sections were incubated with rabbit-anti human CD103
mAb (anti-aEb7-integrin, Abcam, ab129202, 1:200 in blocking
buffer) and incubated at 4C overnight. Slides were incubated
with a peroxidase-labeled polymer (EnvisionC anti-rabbit
Dako) and a Biotin Tyramide working solution according to
the manufacturer’s instructions (TSA Kit Perkin Elmer,
NEL700A001KT). Subsequently, slides were incubated with
streptavidin-HRP (dilution: 1:100) (TSA kit, Perkin Elmer) and
speciﬁc signal visualized by 3,30diaminobenzidin (DAB). Slides
were counterstained with hematoxylin.
The total number of positively stained CD103C cells was
counted per core and the percentage of tumor/stromal surface was
estimated. Patients were included if at least 2 cores contained
>20% tumor epithelium. All slides were counted manually by 2
individuals that were blinded for clinicopathological data. The 2
individual scores were compared and differences in counts of over
10% were reanalyzed until consensus was reached. Cell count was
re-calculated per 1mm2 (i.e. the surface of one core).
Immunoﬂuorescent analysis of CD103C TIL localization
and phenotype
Preparation, antigen retrieval and incubation with primary
CD103 antibody of full tumor slides was performed as
described in immunohistochemistry (IHC). Sections were sub-
sequently incubated with Envision-HRP anti-rabbit followed by
ﬂuorophore tyramide stock solution:ampliﬁcation diluents
(TSA KIT Perkin Elmer,1:50) according to the manufacturer’s
instructions. Slides were incubated overnight at 4C with either
biotinylated rabbit anti-ﬁbronectin (Abcam, ab6584 1:50 in
blocking buffer) or rabbit anti-phospho-SMAD2/3 Mab (cell
signaling, Ser 465/467 #3101, 1:50 in blocking buffer), and
either mouse anti-human CD8 (DAKO, clone C8/144B,
M710301–2, 1:25 in blocking buffer), anti-NKp46 (R&D Sys-
tems, ab1850, 1:25 in blocking buffer), anti-CD3 (Abcam,
ab11089, 1:25 in blocking buffer) or anti-FoxP3 (Abcam,
ab20034, 1:50 in blocking buffer) antibodies. Sections were sub-
sequently incubated with goat-anti-mouse Alexa Fluor 555
(Life Technologies, Eugene,1:150) and streptavidin dylight 488
(Life Technologies, 1:150) Nuclei were visualized with DAPI.
Sections were embedded in prolong Diamond anti-fade mount-
ing medium (Life Technologies, Eugene) and scanned using a
TissueFaxs imaging system (TissueGnostics). Processed chan-
nels were merged using Adobe Photoshop. On each slide 3 to 6
representative epithelial and 3 to 6 stromal areas of 40 mm2
were selected based on DAPI staining. Within each area, single-
positive (CD103-CD8C or CD103CCD8-) cells as well as dou-
ble-positive (CD103CCD8C) cells were counted manually.
Mice
Speciﬁed pathogen-free female C57BL/6 mice were used at 8 to
12 weeks of age at the onset of the experiment. They were pur-
chased from Harlan CPB (Zeist, The Netherlands) and kept
according to institute guidelines. All animal experiments were
approved by the local Animal Experimentation Ethical
Committee.
Tumor inoculation, local tumor irradiation and rSFV
immunization
TC-1 cells were a kind gift from Dr. Cornelis J. Melief and Dr.
Rienk Offringa (Leiden University Medical Center, The
Netherlands). The TC-1 cell line was generated from C57Bl/6
primary lung epithelial cells with a retroviral vector expressing
HPV16 E6E7. All cells were cultured as described before.54
Mice were inoculated subcutaneously in the neck with 2 £ 104
TC-1 cells suspended in 0.2 mL Hank’s Balanced Salt Solution
(Invitrogen,). Fourteen days after injection of TC-1, mice were
locally irradiated with 7 Gy and/or semliki forest virus (SFV)
eE6,7 immunization. Radiation was performed using X-RAD
320 Biological Irradiator (Precision X-Ray) with a delivery rate
of 1.64 Gy/min. Immunization was performed intramuscularly
with a dose of 5 £ 106 i.u. of SFVeE6,7 and boosted twice with
a one-week interval (day 14 and 21) as a suboptimal immuni-
zation regimen. Control mice were injected intramuscularly
with PBS. Tumors were isolated 22 days after TC-1 inoculation.
Tumor digestion and ﬂow cytometry analysis
Tumors isolated from mice were processed as previous
described(51). In brief, pre-warmed Collagenase A (Roche)
solution was used for digestion and tumors were homogenized
using the gentle MACStm Dissociator (Miltenyi Biotec).
Tumors cells were further stained with PeCy7-anti-CD8 (eBio-
science, clone 53–6.7, 25–5273–41) and FITC-anti-CD103 (BD
Biosciences, clone 2E7, 333155). For the dextramer staining,
cell suspensions were ﬁrst washed twice in FACS buffer (PBS
containing 0.5% bovine serum albumin) and stained with PE-
H-2Db E749–57 dextramers (Immudex, Copenhagen, Denmark)
for 10 min at room temperature. Subsequently, the cells were
stained with PE-Cy7-anti-CD8a Ab and FITC-anti-CD103 Ab.
To exclude dead cells, cells were stained with Zombie VioletTM
(Biolegend, 423113).
Statistics
Differences in cell count were determined by a Mann-Whitney
U, Kruskall-Wallis, ANOVA or t-test. Disease-speciﬁc survival
(DSS) and disease-free survival (DFS) were analyzed using a
Kaplan-Meier function; differences in survival were assessed by
log Rank test. DSS was deﬁned as date of diagnosis to date of
death due to disease. DFS was deﬁned as date of diagnosis to
date of recurrence or date of death of disease, in case no recur-
rence was reported previously. Differences in DSS and DFS
according to clinicopathologic characteristics and to inﬁltration
of CD103C TIL were analyzed using the Cox regression analy-
ses. Variables with a p-value <0.05 in the univariate analyses
were included in the multivariate analyses. Signiﬁcance was
deﬁned as a p-value of <0.05, all tests were performed 2-sided.
Statistics were performed using SPSS software version 22.0
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